28 results
424B3
BBLNF
Babylon Holdings Ltd
6 Dec 22
Prospectus supplement
5:22pm
; risks that certain of our software products could become subject to oversight by the United States Food and Drug Administration (“FDA”); risks associated … -Oxley Act of 2002; (iii) not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB
424B3
BBLNF
Babylon Holdings Ltd
5 Dec 22
Prospectus supplement
4:16pm
tax laws; risks that certain of our software products could become subject to oversight by the United States Food and Drug Administration (“FDA … requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement
POS AM
BBLNF
Babylon Holdings Ltd
29 Nov 22
Prospectus update (post-effective amendment)
4:49pm
of our software products could become subject to oversight by the United States Food and Drug Administration (“FDA”); risks associated with medical … ; (iii) not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding
F-3
BBLNF
Babylon Holdings Ltd
23 Nov 22
Shelf registration (foreign)
4:17pm
of our software products could become subject to oversight by the United States Food and Drug Administration (“FDA”); risks associated with medical … by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor’s report providing
6-K
EX-99.2
BBLNF
Babylon Holdings Ltd
10 Nov 22
Babylon Reports Another Strong Quarter Ahead of Consensus Estimates with Revenue Growth of 3.9x and 45 ppts Adjusted EBITDA Margin Improvement
6:03am
litigation or regulatory investigations; Certain of our software products could become subject to U.S. Food and Drug Administration oversight
6-K
EX-99.2
j1k94 w4fuh
9 Aug 22
Babylon Again Delivers Strong Performance with Record Margins for Second Quarter 2022
12:00am
6-K
9tcnxyx5
1 Aug 22
Current report (foreign)
6:00am
424B3
x38u loqidk0x
17 Jun 22
Prospectus supplement
5:01pm
6-K
EX-99.1
82xh1761
23 May 22
1 Capital Markets Day 23 May 2022 Putting an accessible and affordable quality health service in the hands of every person on Earth
6:04am
F-4
EX-10.14
eemce4w4a421h93tat7
20 May 22
Registration of securities (foreign)
5:13pm
F-4
s3kfshgeclx
20 May 22
Registration of securities (foreign)
5:13pm
6-K
EX-99.2
tfw5 pthr3smb
12 May 22
Babylon Delivers Massive Growth and Adjusted EBITDA Margin Improvement in the First Quarter of 2022 and Raises 2022 Revenue Guidance
6:00am
424B3
xf58kgjt
9 May 22
Prospectus supplement
4:15pm
424B3
uxyggkuwlj5ljgkfoa
3 May 22
Prospectus supplement
4:16pm
6-K
EX-99.1
icaca4
3 May 22
1 Babylon 2022 Investor Meetings May 2022
6:06am
F-1
2vw0c5
29 Apr 22
Registration statement (foreign)
5:09pm
POS AM
yfye4
28 Apr 22
Prospectus update (post-effective amendment)
5:28pm
424B3
yucdres8wgir wji
30 Mar 22
Prospectus supplement
5:19pm
20-F
9z0ehsp5t 76
30 Mar 22
Annual report (foreign)
4:12pm
424B4
q5galy84r4zoj79s omn
30 Nov 21
Prospectus supplement with pricing info
5:27pm